Biogen 19th drugmaker to shirk access in 340B program, nonprofit says

Biogen, along with 18 other drugmakers, are shortcutting the 340B law by restricting their involvement in the drug pricing program, nonprofit organization 340B Health said Dec. 13. 

On Dec. 12, Biogen said two of its drugs that treat multiple sclerosis, Avonex and Plegridy, will not be discounted through 340B entities' partner pharmacies. 340B Health President and CEO Maureen Testoni said the decision, which Biogen said will take place Feb. 1, is "depriving safety-net hospitals of needed resources from mandated 340B discounts and keeping those dollars."

The other pharmaceutical companies that have made similar moves are AbbVie, Amgen, AstraZeneca, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Exelixis, Gilead, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, UCB and United Therapeutics, according to 340B Health.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars